Evidence map›Paper›PMID 40843683›Full record

ArticleAntibodies (Basel, Switzerland)2025

Guidelines in the Preparation of Fully Synthetic, Human Single-Domain Antibody Phage Display Libraries.

Mark A Tornetta, Brian P Whitaker, Olivia M Cantwell, Peter N Haytko, Eileen D Pisors, Fulai Zhou, Mark L Chiu

Abstract read
In one paragraph

Article in Antibodies (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mark A TornettaTavotek Biotherapeutics, 727 Norristown Road, Spring House Innovation Park, Building 3, Suite 101, Lower Gwynedd, PA 19002, USA.ORCID 0009-0002-5997-0426
Brian P WhitakerTavotek Biotherapeutics, 727 Norristown Road, Spring House Innovation Park, Building 3, Suite 101, Lower Gwynedd, PA 19002, USA.
Olivia M CantwellTavotek Biotherapeutics, 727 Norristown Road, Spring House Innovation Park, Building 3, Suite 101, Lower Gwynedd, PA 19002, USA.
Peter N HaytkoTavotek Biotherapeutics, 727 Norristown Road, Spring House Innovation Park, Building 3, Suite 101, Lower Gwynedd, PA 19002, USA.
Eileen D PisorsTavotek Biotherapeutics, 727 Norristown Road, Spring House Innovation Park, Building 3, Suite 101, Lower Gwynedd, PA 19002, USA.
Fulai ZhouTavotek Biotherapeutics Building C2, Suzhou Biomedical Industrial Park, Suzhou 215000, China.
Mark L ChiuTavotek Biotherapeutics, 727 Norristown Road, Spring House Innovation Park, Building 3, Suite 101, Lower Gwynedd, PA 19002, USA.ORCID 0000-0001-6300-404X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesThe complexity of diseases such as cancer and auto-immune disorders drives the need for unique, target-driven therapeutics. A broader arsenal to generate better biologics-based therapeutics is needed to provide more efficient and effective antibody generation technologies. The critical parameter for antibody generation is to generate as much candidate diversity to each target as possible. METHOD/

resultsWe present guidelines for having an efficient process using a fully synthetic human single-domain antibody (sdAb) phage display library. Critical milestones for success focused on library quality control (QC) assessments, evaluation of specific biopanning outputs, and construct designs that enabled efficient transition to mammalian expression. The synthetic VHO libraries produced epitope diversity better than an immunized sourced library with candidates possessing nM potencies and monodispersity > 90% via SEC.

conclusionsSynthetic human scaffold sdAb phage display libraries was constructed, biopanned, and selected candidates that could be directly transitioned for mammalian expression. The diverse VHO sets of candidates produced from many targets easily provided opportunities to make a multi-specific biological compound. Both synthetic and immunized phage selection campaign results suggested that these technologies complemented each other to generate therapeutic candidates. Finally, we demonstrated how diverse data produced from a process that used VHO synthetic libraries could accelerate drug discovery.

Indexed as

nanobodyphage displaysingle-domain antibodysyntheticvariable heavy chain

Identifiers

PMID40843683
PMCPMC12371903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.